Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Type 2 Diabetes
Authors:
Open Access
- 21 June 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (6) , e2217709
Abstract
Cigarette smoking is a major risk factor for cardiovascular disease1 and is highly prevalent among patients with type 2 diabetes.2 It is not surprising that smoking exacerbates the combined harmful effects of hyperglycemia and other risk factors, accelerating vascular damage in patients with diabetes.3 Increased risk of total mortality, coronary heart disease, stroke, and peripheral arterial disease has been observed in smokers with diabetes compared with nonsmokers with diabetes.3,4 Consistent with these observations is that stopping smoking has been associated with reduced mortality risk in patients with type 2 diabetes.5,6 Moreover, patients with type 2 diabetes who participated in smoking cessation programs were found to have better glycemic control and lower cardiometabolic risk factors.7 Therefore, counseling on quitting smoking and treatment of tobacco addiction should be components of routine diabetes care.8,9Keywords
This publication has 42 references indexed in Scilit:
- Weight gain in smokers after quitting cigarettes: meta-analysisBMJ, 2012
- Effect of a nicotine-free inhalator as part of a smoking-cessation programmeEuropean Respiratory Journal, 2011
- Circulating endothelial‐coagulative activation markers after smoking cessation: a 12‐month observational studyEuropean Journal of Clinical Investigation, 2010
- A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking CessationClinical Pharmacokinetics, 2010
- Associations between weight change over 8 years and baseline body mass index in a cohort of continuing and quitting smokersAddiction, 2010
- Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular DiseaseCirculation, 2010
- Common predictors of smoking cessation in clinical practiceRespiratory Medicine, 2008
- Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokersClinical Therapeutics, 2007
- Diabetic Patients Who Smoke: Are They Different?The Annals of Family Medicine, 2004
- Smoking and diabetes: Readiness for change and provider adviceAddictive Behaviors, 1999